TSHA PE Ratio & Valuation,Is TSHA Overvalued

TSHA Relative Valuation

TSHA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TSHA is overvalued; if below, it's undervalued.

Historical Valuation

Taysha Gene Therapies Inc (TSHA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 268.10 is considered Overvalued compared with the five-year average of -4.45. The fair price of Taysha Gene Therapies Inc (TSHA) is between 1.93 to 4.38 according to relative valuation methord. Compared to the current price of 5.14 USD , Taysha Gene Therapies Inc is Overvalued By 17.26%.

Relative Value

Fair Zone

1.93-4.38

Current Price：5.14

17.26%

Overvalued

-12.62

-8.60

EV/EBITDA

Taysha Gene Therapies Inc. (TSHA) has a current EV/EBITDA of -8.60. The 5-year average EV/EBITDA is -3.08. The thresholds are as follows: Strongly Undervalued below -7.65, Undervalued between -7.65 and -5.37, Fairly Valued between -0.79 and -5.37, Overvalued between -0.79 and 1.50, and Strongly Overvalued above 1.50. The current Forward EV/EBITDA of -8.60 falls within the Strongly Undervalued range.

-8.42

EV/EBIT

Taysha Gene Therapies Inc. (TSHA) has a current EV/EBIT of -8.42. The 5-year average EV/EBIT is -3.14. The thresholds are as follows: Strongly Undervalued below -7.30, Undervalued between -7.30 and -5.22, Fairly Valued between -1.07 and -5.22, Overvalued between -1.07 and 1.01, and Strongly Overvalued above 1.01. The current Forward EV/EBIT of -8.42 falls within the Strongly Undervalued range.

268.10

Taysha Gene Therapies Inc. (TSHA) has a current PS of 268.10. The 5-year average PS is 44.83. The thresholds are as follows: Strongly Undervalued below -75.23, Undervalued between -75.23 and -15.20, Fairly Valued between 104.87 and -15.20, Overvalued between 104.87 and 164.90, and Strongly Overvalued above 164.90. The current Forward PS of 268.10 falls within the Strongly Overvalued range.

-13.15

P/OCF

Taysha Gene Therapies Inc. (TSHA) has a current P/OCF of -13.15. The 5-year average P/OCF is -4.88. The thresholds are as follows: Strongly Undervalued below -11.20, Undervalued between -11.20 and -8.04, Fairly Valued between -1.72 and -8.04, Overvalued between -1.72 and 1.44, and Strongly Overvalued above 1.44. The current Forward P/OCF of -13.15 falls within the Strongly Undervalued range.

-12.44

P/FCF

Taysha Gene Therapies Inc. (TSHA) has a current P/FCF of -12.44. The 5-year average P/FCF is -4.77. The thresholds are as follows: Strongly Undervalued below -10.80, Undervalued between -10.80 and -7.78, Fairly Valued between -1.76 and -7.78, Overvalued between -1.76 and 1.26, and Strongly Overvalued above 1.26. The current Forward P/FCF of -12.44 falls within the Strongly Undervalued range.

Taysha Gene Therapies Inc (TSHA) has a current Price-to-Book (P/B) ratio of 6.57. Compared to its 3-year average P/B ratio of 8.98 , the current P/B ratio is approximately -26.85% higher. Relative to its 5-year average P/B ratio of 7.52, the current P/B ratio is about -12.67% higher. Taysha Gene Therapies Inc (TSHA) has a Forward Free Cash Flow (FCF) yield of approximately -5.92%. Compared to its 3-year average FCF yield of -46.09%, the current FCF yield is approximately -87.15% lower. Relative to its 5-year average FCF yield of -52.03% , the current FCF yield is about -88.62% lower.

6.57

P/B

Median3y

8.98

Median5y

7.52

-5.92

FCF Yield

Median3y

-46.09

Median5y

-52.03

Competitors Valuation Multiple

The average P/S ratio for TSHA's competitors is 266.28, providing a benchmark for relative valuation. Taysha Gene Therapies Inc Corp (TSHA) exhibits a P/S ratio of 268.10, which is 0.68% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of TSHA increased by 254.00% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.71 to -15.63.

The secondary factor is the Margin Expansion, contributed 32.56%to the performance.

Overall, the performance of TSHA in the past 1 year is driven by P/E Change. Which is more unsustainable.

-100.00%

1.79M → 0.00

Revenue Growth

32.56%

-1.43K → -1.89K

Margin Expansion

321.44%

-3.71 → -15.63

P/E Change

254.00%

1.50 → 5.31

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Taysha Gene Therapies Inc (TSHA) currently overvalued or undervalued?

What is Taysha Gene Therapies Inc (TSHA) fair value?

TSHA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Taysha Gene Therapies Inc (TSHA) is between 1.93 to 4.38 according to relative valuation methord.

How does TSHA's valuation metrics compare to the industry average?

What is the current P/B ratio for Taysha Gene Therapies Inc (TSHA) as of Jan 08 2026?

As of Jan 08 2026, Taysha Gene Therapies Inc (TSHA) has a P/B ratio of 6.57. This indicates that the market values TSHA at 6.57 times its book value.

What is the current FCF Yield for Taysha Gene Therapies Inc (TSHA) as of Jan 08 2026?

As of Jan 08 2026, Taysha Gene Therapies Inc (TSHA) has a FCF Yield of -5.92%. This means that for every dollar of Taysha Gene Therapies Inc’s market capitalization, the company generates -5.92 cents in free cash flow.

What is the current Forward P/E ratio for Taysha Gene Therapies Inc (TSHA) as of Jan 08 2026?

As of Jan 08 2026, Taysha Gene Therapies Inc (TSHA) has a Forward P/E ratio of -12.62. This means the market is willing to pay $-12.62 for every dollar of Taysha Gene Therapies Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Taysha Gene Therapies Inc (TSHA) as of Jan 08 2026?

As of Jan 08 2026, Taysha Gene Therapies Inc (TSHA) has a Forward P/S ratio of 268.10. This means the market is valuing TSHA at $268.10 for every dollar of expected revenue over the next 12 months.

TSHA Valuation